These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 39362905)

  • 21. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
    Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
    BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile.
    Lis R; Touboul C; Halabi NM; Madduri AS; Querleu D; Mezey J; Malek JA; Suhre K; Rafii A
    J Transl Med; 2014 Mar; 12():59. PubMed ID: 24597747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.
    Dobbin ZC; Katre AA; Steg AD; Erickson BK; Shah MM; Alvarez RD; Conner MG; Schneider D; Chen D; Landen CN
    Oncotarget; 2014 Sep; 5(18):8750-64. PubMed ID: 25209969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
    Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
    Lee JK; Liu Z; Sa JK; Shin S; Wang J; Bordyuh M; Cho HJ; Elliott O; Chu T; Choi SW; Rosenbloom DIS; Lee IH; Shin YJ; Kang HJ; Kim D; Kim SY; Sim MH; Kim J; Lee T; Seo YJ; Shin H; Lee M; Kim SH; Kwon YJ; Oh JW; Song M; Kim M; Kong DS; Choi JW; Seol HJ; Lee JI; Kim ST; Park JO; Kim KM; Song SY; Lee JW; Kim HC; Lee JE; Choi MG; Seo SW; Shim YM; Zo JI; Jeong BC; Yoon Y; Ryu GH; Kim NKD; Bae JS; Park WY; Lee J; Verhaak RGW; Iavarone A; Lee J; Rabadan R; Nam DH
    Nat Genet; 2018 Oct; 50(10):1399-1411. PubMed ID: 30262818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
    Lui GYL; Shaw R; Schaub FX; Stork IN; Gurley KE; Bridgwater C; Diaz RL; Rosati R; Swan HA; Ince TA; Harding TC; Gadi VK; Goff BA; Kemp CJ; Swisher EM; Grandori C
    EBioMedicine; 2020 Oct; 60():102988. PubMed ID: 32927276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
    Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
    Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
    Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
    Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Hollis RL; Elliott R; Dawson JC; Ilenkovan N; Matthews RM; Stillie LJ; Oswald AJ; Kim H; Llaurado Fernandez M; Churchman M; Porter JM; Roxburgh P; Unciti-Broceta A; Gershenson DM; Herrington CS; Carey MS; Carragher NO; Gourley C
    Gynecol Oncol; 2024 Jul; 186():42-52. PubMed ID: 38582027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-cell transcriptome analysis revealed heterogeneity in glycolysis and identified IGF2 as a therapeutic target for ovarian cancer subtypes.
    Ji J; Bi F; Zhang X; Zhang Z; Xie Y; Yang Q
    BMC Cancer; 2024 Jul; 24(1):926. PubMed ID: 39085784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating single-cell and spatial transcriptomic analysis to unveil heterogeneity in high-grade serous ovarian cancer.
    Luo H; Wang K; Li B
    Front Immunol; 2024; 15():1420847. PubMed ID: 38975339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
    Andersson E; Arvidsson Y; Swärd C; Hofving T; Wängberg B; Kristiansson E; Nilsson O
    Mod Pathol; 2016 Jun; 29(6):616-29. PubMed ID: 26965582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance.
    Marolt N; Pavlič R; Kreft T; Gjogorska M; Rižner TL
    Biomed Pharmacother; 2024 Aug; 177():117069. PubMed ID: 38968802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive landscape analysis of autophagy in cancer development and drug resistance.
    Li Y; Yin Y; Zhang T; Wang J; Guo Z; Li Y; Zhao Y; Qin R; He Q
    Front Immunol; 2024; 15():1412781. PubMed ID: 39253092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancers.
    Kabeer F; Tran H; Andronescu M; Singh G; Lee H; Salehi S; Wang B; Biele J; Brimhall J; Gee D; Cerda V; O'Flanagan C; Algara T; Kono T; Beatty S; Zaikova E; Lai D; Lee E; Moore R; Mungall AJ; ; Williams MJ; Roth A; Campbell KR; Shah SP; Aparicio S
    Genome Biol; 2024 Jul; 25(1):191. PubMed ID: 39026273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer.
    Tan TZ; Heong V; Ye J; Lim D; Low J; Choolani M; Scott C; Tan DSP; Huang RY
    J Pathol; 2019 Mar; 247(3):305-319. PubMed ID: 30374975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.